Health Care Deal News- April 23, 2012


Brought to you by

April 23, 2012 Issue:


  1. Recent Health Care M&A Deals 
  2. First Quarter M&A Results--
    2011 Saw A total of 249 Deals Worth $34.0 Billion
  3. Spotlight on: Biotechnology
  4. Conference Calendar


Recent Health Care M&A Deals





GlaxoSmithKline plc

Respiratory strategic alliance (Five Prime Therapeutics, Inc.)

$1.16 billion


Merck & Co.

Agreement to develop Vintafolide cancer drug candidate (Endocyte, Inc.)

$1.0 billion







Valeant Pharmaceuticals International, Inc.

Mexican generic drug portfolio (Atlantis Pharma)

$71.0 million


Vanda Pharmaceuticals, Inc.

Rights to VLY-686 (Eli Lilly & Co.)

$100.0 million






SXC Health Solutions

Catalyst Health Solutions, Inc.

$4.4 billion



Get Two Reports for the Price of One ($595 savings)- Offer Extended to 4/30!
Deals have been made. The 2012 Health Care Services Acquisition Report contains knowledge that is crucial to the success of your business, your investments, and your clients. Take advantage of our limited-time 2 for 1 offer—Extended to orders placed through April 30! Buy our 2012 Health Care Services Acquisition Report and receive The 2011 Health Care Services Acquisition Report free! Now that’s a recession resistant deal. Place your order by 4/30 by calling 1-800-248-1668 or order online at


First Quarter M&A Results--
A Total of 249 Deals Announced Worth $34.0 Billion

The first quarter of 2012 saw a strong merger and acquisition market in the health care industry. Based on preliminary figures, a total of 249 deals were announced in 13 sectors worth a combined total of $34.0 billion. While the nine services sectors garnered the majority of the deal volume, the four technology sectors took the lion's share of dollar volume.......Read more 


Is Your Company a Power User of Merger and Acquisition Data?
Drive the price of data down to less than 3 cents per item. Call 1-800-248-1668 to learn about our frequency discounts. Go to, an easy-to-use, award-winning database. This specialized database is an essential 24/7 source for details on health care mergers and acquisitions covering 13 sectors. With approximately 20,000 records of investments and contact names (including e-mail addresses), you’ll get the information you need to make an informed decision any time of the day or night. Call 1-800-248-1668 to learn about our frequency discounts.


Spotlight on: Biotechnology
In March's largest biotech deal, the Belgian firm ThromboGenics NV (Euronext: THR) is entering into an agreement with Novartis AG (NYSE:NVS) for the commercialization of ocriplasmin outside of the United States. This product candidate is indicated for the treatment of symptomatic VMA........Read more

Conference Calendar...Click here to see more